Improving treatment outcomes: tolerability of a fixed-combination clindamycin 1%-benzoyl peroxide 5% hydrating gel as monotherapy or in combination with a retinoid.
Patient adherence to acne therapy is a fundamental element of successful treatment outcomes, which can be increased by the selection of rapidly acting, well-tolerated medications used in simplified regimens. A fixed-combination monotherapy gel containing clindamycin 1% and benzoyl peroxide 5% (C/BPO) has an established safety and efficacy profile through almost a decade of published literature and clinician experience. This unique product may improve a patient's adherence to therapy by providing a well-tolerated and efficacious once-daily monotherapy with multiple mechanisms of action. This article reviews data outlining the enhanced tolerability of the fixed-combination C/BPO gel both alone and when used with a retinoid. The favorable tolerability profile of C/BPO hydrating gel may impart additional benefit to the patient in helping to maintain adherence to treatment.